Ioannis A Mavroudis1,2, Foivos Petridis3, Symela Chatzikonstantinou3, Dimitrios Kazis3. 1. Leeds Teaching Hospitals, Leeds, UK. ioannis.mavroudis@nhs.net. 2. Medical School, Cyprus University, Nicosia, Cyprus. ioannis.mavroudis@nhs.net. 3. Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract
OBJECTIVE: Neurogranin is a postsynaptic protein involved in long-term potentiation and synaptic plasticity. Recent studies have shown increased neurogranin levels in the cerebrospinal fluid of Alzheimer's disease patients, and in patients with mild cognitive impairment. METHOD: We searched the online databases for studies on neurogranin cerebrospinal fluid levels in Alzheimer's disease, mild cognitive impairment and other neurodegenerative disorders, and we did a meta-analysis to clarify whether this can be a reliable biomarker for the diagnosis of Alzheimer's disease, and the discrimination from other disorders. RESULTS: The present meta-analysis showed that neurogranin CSF levels are significantly higher in AD patients compared to NC [SMD: 268.26, 95% CI (143.47, 393.04), Z = 4.21, P = 0.0001], MCI [SMD: 23.45 (15.97, 30.92), Z = 6.15, P < 0.00001], FTD [SMD: 1.91 (0.92, 2.89), Z = 3.80, P < 0.0001], but no significant difference was found between AD and LBD [SMD: 138.51 (- 14.92, 291.95), Z = 1.77, P = 0.08]. Comparison of stable MCI and MCI that progressed to AD showed significantly higher levels in the CSF of MCI patients who progressed to AD, compared to stable MCI patients [SMD: 230.84 (12.54, 449.14), Z = 2.07, P = 0.04]. Neurogranin can also be a useful biomarker for the differentiation MCI and NC, but not between MCI and FTD or LBD. CONCLUSION: Neurogranin could be added to the panel of existing biomarkers for a more accurate diagnosis and progress of AD and assessment of underlying pathological changes in the brain.
OBJECTIVE:Neurogranin is a postsynaptic protein involved in long-term potentiation and synaptic plasticity. Recent studies have shown increased neurogranin levels in the cerebrospinal fluid of Alzheimer's diseasepatients, and in patients with mild cognitive impairment. METHOD: We searched the online databases for studies on neurogranin cerebrospinal fluid levels in Alzheimer's disease, mild cognitive impairment and other neurodegenerative disorders, and we did a meta-analysis to clarify whether this can be a reliable biomarker for the diagnosis of Alzheimer's disease, and the discrimination from other disorders. RESULTS: The present meta-analysis showed that neurograninCSF levels are significantly higher in ADpatients compared to NC [SMD: 268.26, 95% CI (143.47, 393.04), Z = 4.21, P = 0.0001], MCI [SMD: 23.45 (15.97, 30.92), Z = 6.15, P < 0.00001], FTD [SMD: 1.91 (0.92, 2.89), Z = 3.80, P < 0.0001], but no significant difference was found between AD and LBD [SMD: 138.51 (- 14.92, 291.95), Z = 1.77, P = 0.08]. Comparison of stable MCI and MCI that progressed to AD showed significantly higher levels in the CSF of MCI patients who progressed to AD, compared to stable MCI patients [SMD: 230.84 (12.54, 449.14), Z = 2.07, P = 0.04]. Neurogranin can also be a useful biomarker for the differentiation MCI and NC, but not between MCI and FTD or LBD. CONCLUSION:Neurogranin could be added to the panel of existing biomarkers for a more accurate diagnosis and progress of AD and assessment of underlying pathological changes in the brain.
Authors: Tian Qin; Samantha Prins; Geert Jan Groeneveld; Gerard Van Westen; Helga E de Vries; Yin Cheong Wong; Luc J M Bischoff; Elizabeth C M de Lange Journal: Int J Mol Sci Date: 2020-04-30 Impact factor: 5.923
Authors: Johanna Nilsson; Johan Gobom; Simon Sjödin; Gunnar Brinkmalm; Nicholas J Ashton; Johan Svensson; Per Johansson; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Ann Brinkmalm Journal: Alzheimers Dement (Amst) Date: 2021-05-01